Article Text

Download PDFPDF
T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy
  1. P A Csurhes1,
  2. A-A Sullivan1,2,
  3. K Green2,
  4. M P Pender1,2,
  5. P A McCombe1,2,3
  1. 1Neuroimmunology Research Centre, School of Medicine, The University of Queensland, Brisbane, Australia
  2. 2Department of Neurology, Royal Brisbane and Women’s Hospital, Brisbane, Australia
  3. 3Wesley Research Institute, Wesley Hospital, Brisbane, Australia
  1. Correspondence to:
 Dr P A McCombe
 The University of Queensland Department of Medicine, C Floor, Clinical Sciences Building, Royal Brisbane and Women’s Hospital, Herston Q 4029, Brisbane, Australia; p.mccombemedicine.uq.edu.au

Abstract

Objectives: It has been suggested that autoimmunity to peripheral myelin proteins is involved in the pathogenesis of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We aimed to compare reactivity of peripheral blood mononuclear cells (PBMC) to antigens of peripheral myelin proteins in patients with GBS and patients with CIDP with that of healthy controls and patients with other non-immune mediated neuropathies (ON).

Methods: We prepared PBMC from blood from 83 healthy controls and from 64 patients with GBS, 54 with CIDP, and 62 with ON. PBMC were tested in antigen specific proliferation assays against peptides from myelin proteins P0, P2, PMP22, and myelin basic protein (MBP), which is identical to myelin P1, and against whole human MBP. Interferon-gamma (IFN-γ) and interleukin (IL)-5 enzyme linked immunospot (ELISPOT) assays were also performed in some subjects to assess spontaneous and peripheral myelin antigen specific PBMC cytokine secretion.

Results: Antigen specific PBMC proliferation assays showed no significant elevation of peptide specific T cell responsiveness in patients with GBS or CIDP compared with healthy controls or patients with ON. Levels of spontaneous ELISPOT IFN-γ secretion were increased in patients with GBS and significantly increased in those with CIDP compared with healthy controls and patients with ON. No convincing differences in antigen specific ELISPOT IFN-γ secretion levels to individual peptides were detectable in patients with GBS. The proportion of patients with CIDP with an increased number of PBMC producing IFN-γ in response to peptide PMP-2251–64 was significantly increased compared with healthy controls and patients with ON. No significant differences in antigen specific ELISPOT IL-5 secretion levels were detectable in patients with GBS or CIDP compared with controls, but levels of spontaneous IL-5 secretion were significantly higher in patients with CIDP than in healthy controls or patients with ON.

Conclusions: Although the lack of significantly increased antigen specific PBMC proliferation in GBS and CIDP does not support a role for T cells, the more sensitive ELISPOT technique detected increased numbers of PBMC secreting IFN-γ spontaneously in 25% of patients with GBS, providing further evidence for a role of T cells in the immunopathology of GBS. Increased numbers of spontaneous IFN-γ and IL-5 secreting cells, and increased IFN-γ secretion in response to PMP-2251–64, in patients with CIDP provide further evidence for a role of myelin specific T cells in CIDP.

  • AIDP, acute inflammatory demyelinating polyradiculoneuropathy
  • CIDP, chronic inflammatory demyelinating polyradiculoneuropathy
  • EAN, experimental autoimmune neuritis
  • ELISPOT, enzyme-linked immunospot
  • GBS, Guillain-Barré syndrome
  • IFN-γ, interferon-gamma
  • IL5, interleukin 5
  • MBP, myelin basic protein
  • ON, other non-immune mediated neuropathies
  • PBMC, peripheral blood mononuclear cells
  • SFC, spot forming cell
  • SI, stimulation index
  • TNF, tumour necrosis factor
  • Guillain–Barré Syndrome
  • Chronic inflammatory demyelinating polyradiculoneuropathy
  • ELISPOT
  • T-lymphocyte
  • autoimmunity

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests: none declared

  • Ethics approval: This study was approved by the Human Research Ethics committees of the Royal Brisbane, Princess Alexandra, Mater, Greenslopes Private, and Logan Hospitals, as well as the Medical Research Ethics committee of the University of Queensland.